Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
- 19 May 2009
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 94 (7), 1024-1028
- https://doi.org/10.3324/haematol.2008.004440
Abstract
We report serial genetic studies on a young female patient initially diagnosed with asymptomatic smouldering myeloma who progressed to symptomatic myeloma 4.5 years after presentation. An unbalanced translocation, der(14)t(4;14)(p16;q32), was initially found in all plasma cells plus deletions of other chromosomal regions as detected by array-based comparative genomic hybridization. Deletion of chromosome 13 was observed in a minor population of plasma cells (<20%) for the first two years, increasing to 100% of plasma cells by the time of multiple myeloma diagnosis. Loss of 1p and a rearrangement of MYC were first observed in a small population of plasma cells one year prior to the clinical diagnosis of multiple myeloma, but these subclones increased rapidly in size to become the major population suggesting that they were directly involved in the transformation process. This case report provides a unique insight into the mechanisms of disease progression from smouldering multiple myeloma to multiple myeloma.This publication has 23 references indexed in Scilit:
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expressionCell Division, 2006
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Genomic abnormalities in monoclonal gammopathy of undetermined significanceBlood, 2002
- Prognostic features of asymptomatic multiple myelomaBritish Journal of Haematology, 1997
- Smoldering Multiple MyelomaThe New England Journal of Medicine, 1980